Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.
Sogroya® (somapacitan-beco) is a once-weekly treatment option, offering an alternative to once-daily therapy, which may help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results